‹ Back

Understanding 510 (k) and Submission Strategies

December 1, 2025 | CAHIR Solutions

 

 

What a 510(k) Really Is

A 510(k) (Premarket Notification) is a regulatory dossier submitted to the U.S. Food and Drug Administration (FDA) to demonstrate that your device is “as safe and effective” as an already legally marketed device, known as a predicate.

2[]

Instead of proving safety and effectiveness from scratch, you demonstrate substantial equivalence—that your device has the same intended use and either the same, or different but not more risky, technological characteristics compared to the predicate.[1]

Who Actually Needs a 510(k)?

FDA doesn’t define who you are; it defines what actions trigger a 510(k). You must submit when you:]

• Introduce a Class I, II, or certain Class III device (not requiring PMA) into U.S. commercial distribution for the first time, unless the device is explicitly exempt.

• Make certain significant modifications to a legally marketed device, as described later in this post.]

 

The main parties who typically submit a 510(k) include:

• Domestic manufacturers of finished devices that they market under their own name.

• Specification developers who design the device and contract out manufacturing.

• Certain repackers or relabelers whose changes significantly affect labeling or device condition (for example, adding new indications, warnings, or sterilization steps).

• Foreign manufacturers/exporters or their U.S. agents introducing a device into the U.S. market.

 

Component manufacturers, most simple distributors, and many repackagers/relabelers do not submit a 510(k) unless they cross those thresholds.]

When a 510(k) Is Required

FDA expects a 510(k) in several core scenarios.

1. First U.S. Marketing of a Device

If your device was not marketed by your firm before May 28, 1976, and it is not exempt or subject to PMA, you must submit a 510(k) at least 90 days before offering it for sale in the United States.]

FDA must issue a substantial equivalence (SE) order—your “clearance letter”—before you can legally market the device.

2. Significant Changes to an Existing Device

If you hold a cleared 510(k), you must evaluate future changes to your device and ask: could this change significantly affect safety or effectiveness, or does it represent a major change in intended use?

A new 510(k) is required when:1]

• The modification could significantly impact safety or effectiveness (design, components, materials, manufacturing, packaging, sterilization, human factors).

• There is a major change in intended use, such as targeting a new patient population or environment of use.

 

We explore examples of this “when to submit” decision below, because this is where manufacturers most often misstep.

When a 510(k) Is Not Required

You may not need a new 510(k) in several cases, such as:]

• You sell unfinished devices or components that another firm integrates into a finished device.

• Your device is in R&D or clinical evaluation only (though Investigational Device Exemption requirements may apply).

• You distribute another firm’s already cleared device without significantly changing its labeling or condition (for example, using “Manufactured for…” on the label only).[1]

• Your device was legally marketed before May 28, 1976, has not been significantly modified, and you have documentation of “preamendments” status.

• Your device is exempt from 510(k) under 21 CFR 862–892 and does not exceed the specific limitations of that exemption (for example, no new intended use or new fundamental technology).]

 

Cahir Solutions helps clients confirm whether a submission is genuinely needed—or whether robust Quality System documentation alone will suffice.

Understanding Substantial Equivalence

Substantial equivalence is the backbone of every 510(k).]

A device is substantially equivalent if, compared to a predicate device, it:

• Has the same intended use, and

• Has the same technological characteristics, or

• Has different technological characteristics that do not raise different questions of safety and effectiveness, and the data demonstrate it is as safe and effective as the predicate.

Performance evidence may include:

• Bench testing and engineering performance data.

• Biocompatibility, sterility, and electromagnetic compatibility testing.

• Software validation and cybersecurity evidence.

• Clinical data when necessary.

 

If FDA determines your device is not substantially equivalent (NSE), you may either resubmit with new data, pursue the De Novo pathway, seek reclassification, or move to a PMA.

Selecting the right predicate and building a strong equivalence rationale are areas where Cahir Solutions provides significant strategic value.

The Move to eSTAR and Digital Submissions

Starting October 1, 2023, nearly all 510(k) submissions must be provided electronically using eSTAR, FDA’s structured electronic submission template.1]

 

Through FDA’s CDRH Portal, sponsors can:

• Register for an account to submit electronic 510(k) files.

• Send both eSTAR and eCopy premarket submissions online.

• Monitor review progress via an integrated tracker for 510(k)s.

 

Using eSTAR correctly is not just a formatting exercise; it directly affects how efficiently FDA can screen and review your submission. Cahir Solutions supports clients with eSTAR-driven content planning, template completion, and technical QA to minimize Refuse to Accept (RTA) or additional information (AI) requests.1]

When a New 510(k) Is Required for Modifications

Modern devices change frequently—new materials, supply chain substitutions, UI tweaks, connectivity updates, and more. FDA expects you to run each change through a risk‑based assessment, using the Agency’s General Modifications and Software Modifications guidances to decide when a new 510(k) is warranted.

A new 510(k) is required when a legally marketed device is significantly changed or modified in:5]

• Design or components (including form factor, architecture, or critical features).

• Method of manufacture (for example, new processes, new sterilization method).

• Intended use (new indications, patient groups, or environments of use).

“Significant changes” are those that could significantly affect safety or effectiveness, or that constitute a major change in intended use under 21 CFR 807.81(a)(3).]

Examples of Modifications That May Trigger a New 510(k)

FDA provides several illustrative examples of changes that may require a new 510(k), including:

• Changing indications from prescription use to over‑the‑counter use.

• Adding a new patient population, such as pediatrics or a new disease group.

• Moving the environment of use, for example, from hospital professional use to home use.

• Changing frequency or duration of use in a clinically meaningful way.

• Adding compatibility claims with new devices, components, or accessories not previously indicated.

• Modifying sterilization, cleaning, disinfection, or package integrity and shelf‑life claims.

• Redesigning the physical design of the device or employing wireless communication for the first time.

• Changing human factors / user interface, which may impact use errors or user performance.

• Introducing a new material type, formulation, or chemical composition, particularly for patient‑contacting materials.

• Modifying critical reagents or components in in vitro diagnostic (IVD) devices.

 

Each change is evaluated within your Quality System using risk management tools (for example, ISO 14971) and the FDA “when to submit” flowcharts, with clear documentation of your conclusion and rationale.]

Software Changes: A Special Case

Software evolves quickly, so FDA treats software modifications with focused guidance.]

All software tweaks—bug fixes, patches, minor updates—are considered design changes under the Quality System regulation (21 CFR Part 820). Some of these require only internal documentation, while others trigger a new 510(k). Examples that may require a new submission include:4]

• A change that introduces a new risk or modifies an existing risk that could result in significant harm.

• Revisions to risk controls implemented to prevent significant harm.

• Changes that significantly affect clinical functionality or performance specifications of the device.

 

When software changes are combined with hardware or labeling changes, FDA expects manufacturers to apply both the general and software-specific guidance documents. If either path concludes “new 510(k),” you should plan to submit.]

No “Supplements”: How to Submit for Changes

For 510(k) devices, there is no concept of a “supplement” or “amendment” that simply updates an existing clearance once a change crosses the significance threshold.]

Instead:

• If a modification is not covered under the cleared 510(k), a new 510(k) must be submitted.

• A Special 510(k) may be appropriate if the change does not alter the intended use or fundamental scientific technology, and if design control outputs can support the review.]

Cahir Solutions helps teams decide whether a Traditional, Special, or other 510(k) type is the most efficient route and then builds a submission strategy aligned to that pathway.

The Regulatory and Quality System Connection

Even when a new 510(k) is not required, FDA expects all changes to be implemented under a robust Quality System (21 CFR 820) with:

• Documented design controls and verification/validation.

• Comprehensive risk management, including documented rationales for your “new 510(k)?” decisions.

• Change control records that clearly show when and why you did or did not submit a new 510(k).

 

From an FDA inspection perspective, your change files and 510(k) decision logs are often as important as the submission itself. Cahir Solutions works with clients to align regulatory and quality narratives so that what you tell FDA on paper matches what auditors see on site.

 

 

How Cahir Solutions Can Help

Navigating 510(k) expectations is not just about filling in forms—it’s about strategic decisions that can accelerate or delay market entry. Cahir Solutions supports medical device organizations at every stage:

• Regulatory strategy & classification

  • Determining whether a 510(k), De Novo, or PMA is appropriate.

  • Identifying optimal predicate devices and special controls.]

• eSTAR‑ready submission development

  • Mapping your technical file content to FDA’s 510(k) content expectations in 21 CFR 807 and current guidance.

  • Authoring and reviewing 510(k) sections for clarity, consistency, and alignment with substantial equivalence logic.

• Change control and “when to submit” assessments

  • Applying FDA’s General and Software Modifications guidances and flowcharts to your design changes with a defensible, risk‑based rationale.]

  • Building internal decision tools and templates so your teams make consistent, auditable calls on new 510(k) needs.]

• Inspection readiness and lifecycle support

  • Ensuring your design control and risk management records can withstand FDA review for both original and modified devices.

  • Supporting responses to information requests and NSE or deficiency letters if they arise.1]

If your team is planning a first U.S. launch, facing device modifications, or shifting to eSTAR and modern FDA expectations, Cahir Solutions can help you turn regulatory complexity into a structured, confident path to clearance. To discuss your 510(k) or change strategy, contact our team and we’ll meet you where you are—whether that’s a concept on a whiteboard or a near‑final design ready for submission.